Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Malignant perivascular epithelioid cell tumor of the colorectum: Clinicopathological characterization, diagnosis and treatment process of 7 cases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND

          Perivascular epithelioid cell tumor (PEComa) of the colorectum is exceedingly rare, with only a few published reports. It presents with a wide spectrum of biological behavior, ranging from benign to malignant. The prognosis for malignant PEComa is poor and there is little consensus on its treatment.

          AIM

          To fully characterize PEComa and standardize its diagnosis and treatment.

          METHODS

          Patients with colorectal malignant PEComa were identified from the First Affiliated Hospital, Zhejiang University School of Medicine and People's Hospital of Anji. Cases with controversial pathology and cases lost to follow-up were excluded, leaving seven remaining cases that formed the basis of the study. We collected relevant clinicopathological, therapeutic and followup details. Disease stage and progression were assessed by contrast-enhanced computed tomography at baseline and at 3-month intervals.

          RESULTS

          The mean age was 43 years, with a range of 5 years to 73 years. The average body mass index was 21.8 ± 3.0 kg/m 2, and 71.4% of cases occurred in the colon. The main symptoms of colorectal PEComas were abdominal mass and hematochezia. The most common microscopic finding of malignant behavior was infiltrative growth. Immunohistochemical analysis found that 6/7 cases were positive for HMB45, 5/7 were positive for melan-A, and 3/5 were positive for MiTF. The watch-and-wait approach to treatment was a risky option. Radical resection was preferable to systemic treatment. The median progression-free survival exceeded 38 months, longer than previously reported.

          CONCLUSION

          Radical or extended resection is the key to prolonged survival of malignant PEComa. More meaningful studies are urgently needed to establish the standardized diagnosis and treatment.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: not found
          • Article: not found

          Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

              Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab -sirolimus (AMPECT, NCT02494570 ). PATIENTS AND METHODS Patients with malignant PEComa were treated with nab -sirolimus 100 mg/m 2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology review. Key secondary end points included duration of response, progression-free survival, and safety. A key exploratory end point was tumor biomarker analysis. RESULTS Thirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a TSC2 mutation achieved a confirmed response versus 2 of 16 (13%) without TSC2 mutation ( P < .001). The median progression-free survival was 10.6 months (95% CI, 5.5 months to not reached), and the median overall survival was 40.8 months (95% CI, 22.2 months to not reached). Most treatment-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade ≥ 4 treatment-related events occurred. CONCLUSION nab -Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab -sirolimus represents an important new treatment option for this disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                World J Gastrointest Oncol
                WJGO
                World Journal of Gastrointestinal Oncology
                Baishideng Publishing Group Inc
                1948-5204
                15 February 2025
                15 February 2025
                : 17
                : 2
                : 99662
                Affiliations
                Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
                Department of Surgery, People's Hospital of Anji, Huzhou 313300, Zhejiang Province, China
                Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
                Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
                Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
                Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China. 592031959@ 123456qq.com
                Author notes

                Co-first authors: Ming-Fei Ma and Zhen-Yu Chi.

                Author contributions: Ma MF and Chi ZY performed the study and wrote the manuscript; they contributed equally and are therefore co-first authors; Ma MF and Zhao LJ analyzed the data and generated charts; Chi ZY, Zhai W and Zhong W collected patients’ clinical data and conducted follow-up; Wang S designed and supervised the report; All authors have read and approved the final manuscript.

                Corresponding author: Song Wang, MD, PhD, Surgeon, Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. 592031959@ 123456qq.com

                Article
                jWJGO.v17.i2.eid99662 99662
                10.4251/wjgo.v17.i2.99662
                11756007
                2760d901-ca2c-498f-874b-c66b2788202a
                ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

                History
                : 27 July 2024
                : 25 October 2024
                : 22 November 2024
                Categories
                Retrospective Study

                perivascular epithelioid cell tumor,colorectum,malignant,resection,mammalian target of rapamycin inhibitor

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content282

                Most referenced authors331